Erratum to: Rescue strategy for advanced liver malignancy with retrohepatic inferior vena cava thrombi: experience to promote surgical oncological benefit

Meng-Hsing Ho1, Teng-Wei Chen1, Kuang-Wen Ou2, Jyh-Cherng Yu1 and Chung-Bao Hsieh1*

Erratum
Upon publication of the original article [1], an error was discovered in Table 1 (the tumor location of the 9th patient). This mistake was owing to typing error. This has now been corrected in this erratum and the original manuscript has been updated. We apologise for any inconvenience caused by this error.

Author details
1Division of General Surgery, Department of Surgery, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan, Republic of China.
2Divisions of Plastic Surgery and General Surgery, Department of Surgery, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan, Republic of China.

Received: 20 April 2017 Accepted: 20 April 2017 Published online: 28 April 2017

Reference
1. Ho MH, Chen TW, Ou KW, Yu JC, Hsieh CB. Rescue strategy for advanced liver malignancy with retrohepatic inferior vena cava thrombi: experience to promote surgical oncological benefit. World J Surg Oncol. 2017;15(1):83.
### Table 1: Demographic data of patients undergoing curative surgery

| Patient | Sex | Age (y) | Diagnosis                                                                 | Child class (score) | Tumor marker | Location of hepatic tumor | Thrombi location                  | Pre-operative therapy |
|---------|-----|---------|---------------------------------------------------------------------------|---------------------|--------------|--------------------------|-----------------------------------|----------------------|
| 1       | F   | 68      | Leiomyosarcoma of IVC with liver invasion                                  | Non-cirrhosis       | N/A          | Seg 1,2,3                | Reaching the hepatocaval junction | N                    |
| 2       | F   | 46      | HBV-related HCC                                                           | A (5)               | AFP: 5000 ng/dL | Seg 7,8                  | Near the hepatocaval junction     | N                    |
| 3       | M   | 57      | HBV-related HCC                                                           | A (6)               | AFP: 4000 ng/dL | Seg 5,6,7,8              | Reaching the hepatocaval junction | N                    |
| 4       | F   | 38      | Adrenocortical carcinoma with liver                                       | Non-cirrhosis       | N/A          | Seg 4,5,6,7,8            | Reaching the hepatocaval junction | N                    |
| 5       | M   | 72      | HBV-related HCC                                                           | A (5)               | AFP: >40 000 ng/dL | Seg 4,5,6,7,8          | Near the hepatocaval junction     | N                    |
| 6       | M   | 46      | HBV-related HCC                                                           | A (5)               | AFP: >40 000 ng/dL | Seg 7                   | Near the hepatocaval junction     | N                    |
| 7       | M   | 29      | HBV-related HCC                                                           | A (5)               | AFP: >40 000 ng/dL | Seg 5,6,7,8             | Near the hepatocaval junction     | N                    |
| 8       | M   | 46      | HBV-related HCC                                                           | A (5)               | AFP: >40 000 ng/dL | Seg 6,7,8               | Reaching the hepatocaval junction | TACE + Sorafenib     |
| 9       | M   | 86      | Non-HBV or –HCV-related HCC, sacromatoid type                             | A (5)               | AFP: 229 ng/dL  | Seg 4                   | Reaching the hepatocaval junction | TACE + Sorafenib     |
| 10      | M   | 40      | HBV-related HCC                                                           | A (5)               | AFP: 168.5 ng/dL | Seg 5,6                 | Reaching the hepatocaval junction | TACE + Sorafenib     |

**Mean** 52.8  
**SD** 17.7

*AFP* alpha-fetoprotein, *HBV* hepatitis B virus, *F* female, *HCC* hepatocellular carcinoma, *HCV* hepatitis C virus, *M* male, *TACE* transarterial chemoembolization